- Published on
Toxicology-Tacrine
1. Overview
Description
Tacrine is a centrally acting, reversible cholinesterase inhibitor that increases the availability of acetylcholine within the central nervous system. It was developed primarily to improve cognitive function in patients with Alzheimer’s disease. Although tacrine has therapeutic effects on cholinergic neurotransmission, excessive exposure may produce cholinergic toxicity, resulting in gastrointestinal, cardiovascular, respiratory, and neurological complications.
Forms and Clinical Uses
Tacrine, previously marketed under the brand name Cognex, was used in the treatment of Alzheimer’s disease to improve cognitive performance by increasing acetylcholine activity in the brain. It has also occasionally been used as a prolonged-acting acetylcholinesterase inhibitor in the management of anticholinergic poisoning. However, its clinical use has been limited by concerns regarding hepatotoxicity and the availability of alternative treatments.
Toxic Dose
The original toxicology reference estimates the potentially lethal dose of tacrine in adults to be approximately 30 mg/kg. However, this estimate should not be regarded as a firmly established human lethal threshold because clinical information on severe tacrine overdose is limited. The severity of poisoning depends on the amount ingested, individual susceptibility, underlying medical conditions, and the presence of other substances.
2. Pathophysiology
Tacrine acts by reversibly inhibiting cholinesterase, particularly within the central nervous system. This inhibition reduces the breakdown of acetylcholine, resulting in increased concentrations of this neurotransmitter in the brain. At therapeutic doses, enhanced cholinergic activity may temporarily improve cognitive function in individuals with Alzheimer’s disease. Tacrine has relatively limited peripheral effects compared with some other cholinesterase inhibitors. However, excessive exposure can produce significant cholinergic stimulation, leading to manifestations of cholinergic excess such as increased secretions, gastrointestinal hyperactivity, bradycardia, bronchospasm, and neurological disturbances.
3. Epidemiology
Human cases of tacrine overdose have been infrequently documented, making the precise incidence and severity of poisoning difficult to establish. Available historical reports suggest that many exposures may result in mild to moderate toxicity that responds to supportive and symptomatic treatment. Fatal outcomes are considered uncommon, although severe poisoning may occur, particularly following substantial ingestion, the development of serious complications, or simultaneous exposure to other toxic substances.
4. Causes of Poisoning
Tacrine poisoning may occur following accidental ingestion, medication errors, inappropriate dosing, or deliberate overdose. In infants younger than one year, unexplained drug exposure should raise consideration of possible neglect or abuse when supported by the circumstances. In older children, adolescents, and adults, intentional ingestion should be considered when the clinical presentation or exposure history suggests possible self-harm. A careful assessment of the circumstances surrounding ingestion is essential to distinguish accidental exposure from deliberate poisoning.
5. Pregnancy and Lactation
Tacrine was historically classified under Pregnancy Category C by the United States Food and Drug Administration (FDA). This former classification indicated that animal studies demonstrated adverse fetal effects, including potential teratogenic or embryotoxic effects, without adequate controlled studies in pregnant women, or that sufficient reproductive safety information was unavailable. The FDA has since replaced these letter categories with narrative pregnancy risk labeling. The original reference provides no specific information regarding tacrine exposure during breastfeeding, and its safety during lactation remains insufficiently established.
6. Clinical Manifestations and Symptoms
Vital Signs
Bradycardia is an important cardiovascular manifestation of tacrine toxicity and may occur as a result of excessive cholinergic stimulation. In severe poisoning, cardiovascular instability may develop, particularly when significant conduction abnormalities or hypotension are present.
Head, Eyes, Ears, Nose, and Throat (HEENT)
Miosis, or constriction of the pupils, may be observed following tacrine overdose. This finding reflects increased cholinergic activity and may occur alongside other muscarinic manifestations of poisoning.
Dermatological Manifestations
Excessive sweating, also known as diaphoresis, may develop in patients experiencing tacrine-induced cholinergic excess. This manifestation is associated with stimulation of cholinergic pathways controlling sweat gland activity.
Cardiovascular Manifestations
Tacrine overdose may produce significant cardiovascular complications, particularly in cases of substantial ingestion. These effects include marked bradycardia, disturbances in cardiac conduction, and varying degrees of atrioventricular block. In severe cases, profound cholinergic stimulation may contribute to asystole and cardiovascular collapse.
Pulmonary Manifestations
Respiratory complications associated with tacrine poisoning may include bronchospasm, increased bronchial secretions, and pulmonary edema. These effects can interfere with normal ventilation and oxygenation, potentially leading to respiratory distress or failure in severe cases. Patients with significant respiratory manifestations require prompt assessment and appropriate airway support.
Gastrointestinal Manifestations
Gastrointestinal disturbances are prominent features of tacrine toxicity because increased cholinergic activity stimulates intestinal motility and secretions. Patients may experience severe nausea, vomiting, abdominal discomfort, and diarrhea. Persistent gastrointestinal symptoms may result in dehydration and clinically significant disturbances in fluid and electrolyte balance.
Hepatic Manifestations
Hepatotoxicity is an important adverse effect associated with therapeutic tacrine administration. Historical clinical data indicate that elevations in liver enzymes may occur in approximately 50% of treated patients, commonly within the first one to three months after initiation of therapy. Hepatic abnormalities are usually reversible after discontinuation of the medication. Nevertheless, severe hepatic injury, permanent liver damage, and hepatic failure have been reported. Patients receiving tacrine therefore require careful assessment for evidence of liver dysfunction.
Fluid and Electrolyte Disturbances
Severe vomiting and diarrhea may cause substantial fluid depletion and electrolyte abnormalities. Patients may develop hypokalemia and disturbances in acid-base balance. Metabolic alkalosis may occur with persistent vomiting, whereas significant diarrhea may produce other acid-base disturbances. These complications can contribute to weakness, cardiovascular instability, and worsening clinical symptoms.
Neurological Manifestations
Neurological complications of tacrine overdose may include seizures resulting from excessive central cholinergic stimulation. Worsening of parkinsonian manifestations has also been described in animal studies and at least one human report. Severe neurological toxicity may require urgent intervention to prevent complications associated with prolonged seizure activity or impaired consciousness.
7. Diagnosis
Differential Diagnosis
Tacrine poisoning should be differentiated from other toxicological conditions that produce a cholinergic syndrome. Important alternative causes include poisoning by organophosphate or carbamate insecticides, exposure to chemical nerve agents, and excessive administration of other cholinesterase inhibitors such as edrophonium. These substances may produce similar manifestations, including vomiting, diarrhea, diaphoresis, miosis, bradycardia, and respiratory abnormalities. Diagnosis requires careful consideration of the exposure history, clinical findings, and relevant laboratory investigations.
Essential Laboratory Investigations
Routine laboratory investigations may not be necessary in patients who remain completely asymptomatic after a limited exposure and have no concerning co-ingestions. However, laboratory evaluation is appropriate when significant symptoms develop, substantial ingestion is suspected, or underlying medical conditions increase the risk of complications.
Assessment of Respiratory Function
Pulse oximetry should be used to monitor oxygen saturation in symptomatic patients. Arterial blood gas analysis may be required in individuals with respiratory distress, impaired ventilation, or suspected acid-base disturbances. These investigations help determine the severity of respiratory involvement and guide supportive management.
Electrocardiographic Evaluation
An electrocardiogram (ECG) is recommended in symptomatic or significant overdose cases to identify bradycardia, atrioventricular block, and other cardiac conduction abnormalities. Continuous cardiac monitoring may be necessary in patients with clinically important cardiovascular manifestations.
Biochemical Investigations
Serum electrolytes, blood glucose, blood urea nitrogen (BUN), and creatinine should be measured when patients experience substantial gastrointestinal fluid loss or develop altered mental status. These investigations help identify dehydration, electrolyte disturbances, renal impairment, and metabolic abnormalities that may contribute to clinical deterioration.
Liver Function Assessment
Liver function tests should be considered following significant acute tacrine overdose and in symptomatic patients receiving chronic treatment. Measurement of hepatic enzymes is particularly important because tacrine is associated with potentially serious hepatotoxicity. Serial testing may be required when abnormalities are detected.
Cholinesterase Activity
Reduced cholinesterase activity in plasma or serum may support a diagnosis of exposure to cholinesterase-inhibiting substances. However, these measurements are not specific for tacrine poisoning, and their usefulness depends on the clinical circumstances and testing method. The diagnosis should primarily be based on the history of exposure and the presence of compatible clinical manifestations.
Screening for Co-Ingestants and Neurological Disorders
In suspected intentional or mixed-drug overdose, serum acetaminophen and salicylate concentrations may be obtained to identify potentially dangerous co-ingestions. Patients presenting with altered mental status may require additional investigations, including toxicology screening, cranial computed tomography (CT), lumbar puncture, or microbiological cultures, depending on the suspected underlying cause.
8. Treatment and Management
General Supportive Management
The treatment of tacrine poisoning primarily involves supportive care and management of cholinergic manifestations. Initial evaluation should focus on airway protection, breathing, circulation, and neurological function. Atropine is the principal medication used to counteract clinically significant muscarinic effects. Patients with severe respiratory compromise, reduced consciousness, or inadequate airway protection may require endotracheal intubation and mechanical ventilation. The estimated dose, timing of ingestion, and possibility of additional toxic exposures should be established whenever possible.
Consultation With a Poison Control Center
Consultation with a poison control center or medical toxicologist is recommended when patients develop severe or persistent symptoms. Specialist advice is also appropriate when suspected co-ingestants, medication interactions, or underlying medical conditions complicate the clinical presentation or treatment.
Referral to a Healthcare Facility
Patients should be referred for emergency medical evaluation when intentional poisoning, self-harm, or assault is suspected. Hospital assessment is also indicated when toxic manifestations occur or when co-ingested substances, drug interactions, or pre-existing diseases increase the likelihood of serious complications.
Hospital Admission Considerations
Hospital admission is recommended for patients who continue to exhibit cholinergic symptoms despite initial treatment or develop significant complications. Important indications include persistent bradycardia, hypotension, respiratory impairment, seizures, or cardiac conduction abnormalities. Patients with severe manifestations may require continuous monitoring in a high-dependency or intensive care setting.
9. Decontamination
Out-of-Hospital Management
Induction of vomiting is not recommended following suspected tacrine ingestion because it may increase the risk of aspiration and other complications. Management outside the hospital should prioritize urgent medical assessment when significant exposure or symptoms are present.
In-Hospital Management
The historical reference describes gastric lavage as an option for patients presenting within one hour of a substantial ingestion or experiencing serious toxic effects. It specifies lavage tube sizes of 24–32 French for pediatric patients and 36–42 French for adults. However, gastric lavage is not routinely recommended in contemporary poisoning management because its potential benefits are uncertain and it carries important procedural risks. Its use should be restricted to exceptional circumstances following specialist assessment.
Activated Charcoal Administration
Activated charcoal may be considered after a substantial recent ingestion when the anticipated benefit outweighs the risk of aspiration. The original reference describes a single dose of 1–2 g/kg without a cathartic. Administration should be individualized according to the patient’s clinical condition, timing of exposure, and ability to protect the airway. Activated charcoal should not be administered routinely to patients with reduced consciousness or uncontrolled vomiting unless the airway is adequately protected.
10. Antidotes and Specific Treatment
Atropine Therapy
Atropine is the primary antidotal treatment for the muscarinic manifestations of tacrine-induced cholinergic poisoning. It competitively blocks muscarinic acetylcholine receptors, thereby reducing excessive cholinergic effects on the respiratory tract, cardiovascular system, and other organs. The main therapeutic objective is to control excessive bronchial secretions and improve oxygenation and ventilation.
The historical reference recommends an initial intravenous atropine dose of 1–2 mg for adults and 0.05 mg/kg for pediatric patients, with repeated administration at intervals of approximately 5–10 minutes according to clinical response. These doses are from the supplied source rather than an individualized treatment protocol. In current practice, atropine administration should be guided by the severity of muscarinic manifestations, clinical response, and specialist toxicology recommendations. Treatment should be titrated to adequate respiratory function and control of secretions rather than pupil size alone.
11. Adjunctive Treatment
Management of Seizures
Seizures associated with tacrine toxicity should be treated promptly to reduce the risk of neurological injury and systemic complications. Benzodiazepines are generally used as first-line therapy for toxicologically induced seizures. Persistent or recurrent seizures may require escalation of treatment and intensive monitoring.
Management of Bronchospasm
Bronchospasm resulting from excessive cholinergic stimulation should be managed with atropine to counteract muscarinic effects. Nebulized albuterol or another appropriate bronchodilator may be administered as additional therapy when bronchoconstriction persists. Oxygen supplementation and ventilatory support should be provided when clinically indicated.
Management of Fluid and Electrolyte Disturbances
Patients experiencing severe vomiting or diarrhea may require intravenous fluid replacement and correction of electrolyte abnormalities. Particular attention should be given to potassium concentrations and acid-base disturbances. Fluid management should be individualized according to the degree of dehydration, cardiovascular status, renal function, and ongoing gastrointestinal losses.
12. Follow-Up and Patient Monitoring
Cardiovascular Monitoring
Symptomatic patients should undergo continuous cardiac monitoring to detect bradycardia, heart block, and other conduction disturbances. Intravenous access should be established to facilitate administration of fluids, medications, and emergency treatment if cardiovascular instability develops.
Monitoring of Liver Function
Serial liver enzyme measurements may be necessary in patients with evidence of tacrine-associated hepatic injury. Monitoring helps determine whether liver abnormalities are improving, remaining stable, or progressing. Persistent abnormalities or worsening hepatic function should prompt further medical evaluation and specialist management.
Neurological and Respiratory Monitoring
Patients with significant poisoning should be observed for seizures, changes in mental status, excessive respiratory secretions, bronchospasm, and impaired oxygenation. Repeated clinical assessment is important because worsening cholinergic effects may require additional atropine administration or advanced respiratory support.
13. Expected Clinical Course and Prognosis
Clinical manifestations of acute tacrine poisoning are generally expected to develop within the first several hours after ingestion. Most patients are anticipated to recover with appropriate supportive treatment and management of cholinergic symptoms. The prognosis is usually favorable when complications are recognized and treated promptly. However, prolonged hypotension, severe seizures, respiratory failure, or other serious complications may result in persistent injury. Tacrine-associated hepatic dysfunction also requires follow-up because severe liver injury has occasionally been reported.
14. Discharge Criteria and Instructions
Discharge From the Emergency Department
The historical reference suggests that asymptomatic patients may be considered for discharge after appropriate assessment, any indicated gastrointestinal decontamination, and an observation period of approximately six hours. However, the duration of observation should be individualized according to the amount ingested, clinical findings, co-ingestants, and toxicology recommendations. Psychiatric or psychosocial evaluation should be completed before discharge when intentional self-harm is suspected.
Discharge From the Hospital
Hospitalized patients may be considered for discharge once cholinergic manifestations have resolved or are clearly improving, cardiovascular and respiratory functions are stable, and no further acute treatment is required. In patients with hepatic involvement, liver enzyme trends should demonstrate improvement or an appropriate follow-up plan should be established. Patients admitted following intentional overdose should undergo a suitable mental health assessment before discharge.
15. Diagnostic and Treatment Considerations
Diagnostic Considerations
An important diagnostic challenge is recognizing tacrine poisoning in patients presenting with symptoms common to other cholinesterase inhibitor exposures. Vomiting, diarrhea, sweating, miosis, and bradycardia may resemble organophosphate or carbamate poisoning. Failure to obtain a comprehensive medication and exposure history may delay the diagnosis and appropriate treatment. Clinicians should also consider hepatic injury in patients receiving tacrine who develop unexplained gastrointestinal symptoms or abnormal liver function tests.
Treatment Considerations
Failure to recognize severe muscarinic manifestations, particularly bronchial hypersecretion and bradycardia, may lead to inadequate treatment and clinical deterioration. Airway protection and respiratory support are essential in patients with significant cholinergic toxicity. Atropine should be administered according to the clinical response, with particular attention to respiratory secretions and cardiovascular stability. Inappropriate gastrointestinal decontamination, especially in patients with impaired consciousness or persistent vomiting, may increase the risk of aspiration.
16. International Classification of Diseases (ICD)
The historical ICD-9-CM code 971 refers to poisoning by medications primarily affecting the autonomic nervous system. This classification encompasses poisoning involving drugs that alter autonomic neurotransmission, including cholinesterase inhibitors such as tacrine. The code was included in the original toxicology reference and belongs to the older ICD-9-CM classification system.
17. Conclusion
Tacrine is a centrally acting, reversible cholinesterase inhibitor that was used in the treatment of Alzheimer’s disease. Its toxicity is primarily associated with excessive cholinergic activity, which may produce gastrointestinal disturbances, diaphoresis, miosis, bradycardia, bronchospasm, and seizures. Severe poisoning can lead to respiratory compromise, cardiac conduction abnormalities, and cardiovascular collapse. In addition to its acute toxic effects, tacrine is associated with clinically important hepatotoxicity, particularly during prolonged therapeutic administration.
Management of tacrine poisoning focuses on supportive care, maintenance of respiratory and cardiovascular function, and administration of atropine for significant muscarinic manifestations. Benzodiazepines may be required for seizures, while intravenous fluids and electrolyte replacement may be necessary in patients with substantial gastrointestinal losses. Careful clinical monitoring, assessment for co-ingestants, and appropriate follow-up are important for preventing complications. The prognosis is generally favorable when poisoning is recognized promptly and serious manifestations are treated effectively.